

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Letermovir for prophylaxis of cytomegalovirus reactivation or disease in people with sero-positive cytomegalovirus who have had an allogeneic haematopoietic stem cell transplant [ID1153]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<u>Company(ies)</u> <ul style="list-style-type: none"> Merck, Sharp & Dohme (letermovir) 	<u>General</u> <ul style="list-style-type: none"> All Wales Therapeutic and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary British Society of Blood and Marrow Transplantation Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Association for Primary Care National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation Scottish Medicines Consortium United Kingdom National Screening Committee Welsh Health Specialised Services Committee
<u>Patient/carer groups</u> <ul style="list-style-type: none"> African Caribbean Leukaemia Trust Anthony Nolan Bone Marrow Trust Black Health Agency Bloodwise Cancer52 Cancer Black Care Cancer Equality Chronic Lymphocytic Leukaemia Support Association Chronic Myeloid Leukaemia Support Group CMV Action DKMS Equalities National Council HAWC Helen Rollason Cancer Charity Independent Cancer Patients Voice Leukaemia Cancer Society Leukaemia Care Lymphoma Association Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Primary Immunodeficiency UK South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Primary Immunodeficiency 	<u>Possible comparator companies</u> <ul style="list-style-type: none"> Actavis (aciclovir, valaciclovir) Accord Healthcare (valganciclovir) Aurobindo (valaciclovir, valganciclovir) Clinigen (foscarnet) GlaxoSmithKline (aciclovir, valaciclovir) Hospira (aciclovir)

National Institute for Health and Care Excellence

Final matrix for the technology appraisal of letermovir for prophylaxis of cytomegalovirus reactivation or disease in people with sero-positive cytomegalovirus who have had an allogeneic haematopoietic stem cell transplant

Consultees	Commentators (no right to submit or appeal)
<p>Network</p> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> British Blood Transfusion Society British Committee for Standards in Haematology British Geriatrics Society British Institute of Radiology British society of Immunology British Psychosocial Oncology Society (BPOS) British Transplantation Society Cancer Research UK NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiology The British Society for Haematology UK Chronic Lymphocytic Leukaemia Forum UK Clinical Pharmacy Association UK Health Forum <p><u>Others</u></p> <ul style="list-style-type: none"> Department of Health NHS England NHS Barnet CCG NHS East and North Hertfordshire CCG Welsh Government 	<ul style="list-style-type: none"> Roche Products (valganciclovir) Rosemont (aciclovir) Sun pharmaceutical (acyclovir, valaciclovir) Thame Laboratories (aciclovir) Thorton & Ross (aciclovir) Wockhardt (aciclovir) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> Cochrane Haematological Malignancies Group European Group for Blood and Marrow Transplantation Leuka Leukaemia Busters Lymphoma Research Trust MRC Clinical Trials Unit National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> Public Health England Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Care Excellence

Final matrix for the technology appraisal of letermovir for prophylaxis of cytomegalovirus reactivation or disease in people with sero-positive cytomegalovirus who have had an allogeneic haematopoietic stem cell transplant

Issue date: January 2018

Page 3 of 4

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.